Comment
. 2008 Nov 20;26(33):5489-91; author reply 5491-2.
doi: 10.1200/JCO.2008.19.4118.
Epub 2008 Oct 27.
Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies
- PMID: 18955438
- DOI: 10.1200/JCO.2008.19.4118
Item in Clipboard
Comment
Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies
J Clin Oncol.
.
No abstract available
Comment on
-
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.J Clin Oncol. 2008 Apr 10;26(11):1789-96. doi: 10.1200/JCO.2007.14.8957. Epub 2008 Mar 17. J Clin Oncol. 2008. PMID: 18347005
Similar articles
-
Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy.Clin Lymphoma Myeloma. 2007 Jan;7(4):286-90. doi: 10.3816/clm.2007.n.004. Clin Lymphoma Myeloma. 2007. PMID: 17324336
-
Fcγ receptor predictive genomic testing and the treatment of indolent non-Hodgkin lymphoma.Clin Lymphoma Myeloma Leuk. 2010 Oct;10(5):321-2. doi: 10.3816/CLML.2010.n.063. Clin Lymphoma Myeloma Leuk. 2010. PMID: 21030343 No abstract available.
-
Clearance of red cells by monoclonal IgG3 anti-D in vivo is affected by the VF polymorphism of Fcgamma RIIIa (CD16).Clin Exp Immunol. 2003 Apr;132(1):81-6. doi: 10.1046/j.1365-2249.2003.02119.x. Clin Exp Immunol. 2003. PMID: 12653840 Free PMC article.
-
Fcγ receptor polymorphisms and clinical efficacy of rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia.Clin Lymphoma Myeloma Leuk. 2010 Oct;10(5):347-52. doi: 10.3816/CLML.2010.n.067. Clin Lymphoma Myeloma Leuk. 2010. PMID: 21030347 Review.
-
A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer.J Hematol Oncol. 2013 Jan 4;6:1. doi: 10.1186/1756-8722-6-1. J Hematol Oncol. 2013. PMID: 23286345 Free PMC article. Review.
Cited by
-
Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma.Br J Clin Pharmacol. 2009 Oct;68(4):561-73. doi: 10.1111/j.1365-2125.2009.03494.x. Br J Clin Pharmacol. 2009. PMID: 19843059 Free PMC article.
-
Genetic Susceptibility to ANCA-Associated Vasculitis: State of the Art.Front Immunol. 2014 Nov 17;5:577. doi: 10.3389/fimmu.2014.00577. eCollection 2014. Front Immunol. 2014. PMID: 25452756 Free PMC article. Review.
-
Association of IgG1 Antibody Clearance with FcγRIIA Polymorphism and Platelet Count in Infliximab-Treated Patients.Int J Mol Sci. 2021 Jun 3;22(11):6051. doi: 10.3390/ijms22116051. Int J Mol Sci. 2021. PMID: 34205175 Free PMC article.
-
Genetic polymorphism of the inhibitory IgG Fc receptor FcgammaRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab.Leuk Lymphoma. 2009 May;50(5):723-7. doi: 10.1080/10428190902829441. Leuk Lymphoma. 2009. PMID: 19452316 Free PMC article.
-
Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone.Haematologica. 2012 Jun;97(6):937-42. doi: 10.3324/haematol.2011.050419. Epub 2012 Jan 22. Haematologica. 2012. PMID: 22271896 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
